Health and Healthcare
Pfizer Sneaks By Earnings Estimates (PFE, MRK)
Published:
Last Updated:
Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company’s guidance may be getting in the way a bit. The drug giant turned in results of $0.50 EPS on sales of about $16.7 billion. Thomson Reuters had estimates of $0.47 EPS. The guidance and results are meant to reflect unfavorable changes in foreign exchange due to a stronger U.S. dollar. Today’s news will set up the trend for Merck & Co, Inc. (NYSE: MRK) earnings later this week.
As far as 2012 is concerned, Pfizer is targeting $2.20 to $2.30 earnings per share, which is slightly under prior targets and is currently compared to a Thomson Reuters consensus of $2.28 EPS. The new 2012 guidance for sales is $60.5 billion to $62.5 billion versus a prior range of $62.7 billion to $64.7 billion. The Thomson Reuters consensus is $2.30 EPS for this coming year.
The company noted:
Pfizer has been trading up and down in the early hours of the pre-market and shares are up 0.3% at $21.65 on last look against a 52-week range of $16.63 to $22.17.
JON C. OGG
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.